BRAF gene mutation assessment is indicated in colorectal cancer, advanced non-small cell lung cancer, melanoma and thyroid cancer. BRAF StripAssays^® identify the most relevant mutations in the BRAF gene.

BRAF

• BRAF encodes a serine/threonine protein kinase, which plays an important role in signaling pathways involved in cell proliferation and differentiation.
• Determination of BRAF V600 mutational status is recommended in metastatic colorectal cancer (mCRC) at the same time as RAS mutational status for prognostic assessment (and/or potential selection for clinical trials).
• Testing of patients with metastatic melanoma or advanced non-small cell lung cancer for BRAF V600 mutations prior to treatment is recommended, as BRAF V600 mutation positive patients may benefit from BRAF inhibitor therapy (e.g. dabrafenib, trametinib, vemurafenib).

Citations:

1. Omar B., et al., 2022. Tumor profiling of KRAS, BRAF, and NRAS gene mutations in patients with colorectal cancer: A Lebanese major center cohort study. Gene vol. 834: 146646. doi:10.1016/j.gene.2022.146646.

 2. Fakhruddin N., et al., 2017. BRAF and NRAS Mutations in Papillary Thyroid Carcinoma and Concordance in BRAF Mutations Between Primary and Corresponding Lymph Node Metastases. Scientific reports vol. 7,1 4666. doi:10.1038/s41598-017-04948-3.